SLC5A2 and type 2 diabetes mellitus: explored the racial/ethnic patterns in cardiovascular outcomes in trials of antidiabetic medications in people with T2D.52 A major strength of this review was the fact that they evaluated several antidiabetic medications in addition to SGLT2-Is and GLP1RAs, which included DPP-4 inhibitors, basal insulin, peroxisome proliferator-activated receptor antagonists and alpha glucosidase inhibitors.